Key facts
- LiVeritas Biosciences’s last known valuation is $1.4M (May 2020).
- It has raised $150K; the latest was Later Stage VC in Mar 2025.
- Notable investors include Expert DOJO, Dan Lok Ventures, Kapwa Capital.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for LiVeritas Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for LiVeritas Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LiVeritas Biosciences
Developer of drug development analytics platform intended to deliver quality data at a lower cost and faster turn-around time. The company offers analytical test packages, mass spectrometry digitization, analytical operations and drug product knowledge management, enabling biopharma companies to fast-track drug research and development processes.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2020
- Employees
- 10
- Website
- liveritas.bio/
- Ownership
- Privately Held (backing)
LiVeritas Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LiVeritas Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LiVeritas Biosciences in its N-PORT filings yet. We sweep new filings monthly.